Duloxetine Delayed-Release Capsules recalled over manufacturing violations
- Recall date
- November 14, 2024
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Amerisource Health Services LLC recalls Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-…
- Recall number
- D-0100-2025
- FDA classification
- Class II
- Brand / firm
- Amerisource Health Services LLC
- Sold / distributed
- PA, OH, PR
Why it was recalled
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories
Get recall alerts
Free email alert whenever Amerisource Health Services LLC has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Amerisource Health Services LLC